From The Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115
Received for publication, February 17, 2003, and in revised form, March 18, 2003
![]() |
ABSTRACT |
---|
![]() ![]() ![]() ![]() ![]() ![]() |
---|
Smac, second mitochondria-derived activator of
caspases, promotes apoptosis via activation of caspases. Previous
studies have shown that c-Jun NH2-terminal
kinase (JNK) is involved in regulating another mitochondrial protein,
cytochrome c during apoptosis; however, the role of JNK in
the release of mitochondrial Smac is unknown. Here we show that
induction of apoptosis in multiple myeloma (MM) cells is
associated with activation of JNK, translocation of JNK from cytosol to
mitochondria, and release of Smac from mitochondria to cytosol.
Blocking JNK either by dominant-negative mutant (DN-JNK) or cotreatment
with a specific JNK inhibitor, SP600125, abrogates both stress-induced
release of Smac and induction of apoptosis. These findings demonstrate
that activation of JNK is an obligatory event for the release of Smac
during stress-induced apoptosis in MM cells.
The cellular response to diverse classes of stress inducers
includes growth arrest and induction of apoptosis. Apoptosis is triggered through a controlled program that is associated with distinctive morphological changes including membrane blebbing, cytoplasmic and nuclear condensation, chromatin aggregation, and formation of apoptotic bodies (1). The induction of apoptosis involves
a cascade of initiator and effector caspases that are activated
sequentially (2, 3). Caspases, a family of cysteine proteases with
aspartate substrate specificity, are present in cells as catalytically
inactive zymogens (2). Once activated, the effector caspases induce
proteolytic cleavage of various cellular targets, including
poly(ADP-ribose) polymerase
(PARP)1 (4),
DNA-dependent protein kinase, protein kinase C- One of the major caspase cascades is triggered by the release of
mitochondrial apoptogenic protein, cytochrome c
(cyto-c) (5, 6). Cytosolic cyto-c binds to the
CED-4 homolog Apaf-1 and induces caspase-9-dependent
activation of caspase-3 (7). Recent studies have identified another
important regulator of apoptosis, Smac (second mitochondria-derived
activator of caspase) or DIABLO, which is released from mitochondria
into the cytosol during apoptosis (8, 9) and functions by eliminating
inhibitory effects of inhibitor of apoptosis proteins on
caspase-9 (9, 10). Our prior studies showed that 2ME2-induced apoptosis
in MM cells involves release of both cyto-c and Smac (11).
However, the upstream signal that triggers the 2ME2-induced
mitochondrial apoptotic pathways in MM cells is unclear.
A recent study has shown that stress-activated protein kinase (SAPK) or
c-Jun NH2-terinal Kinase (JNK) mediates the release of
cyto-c during apoptosis (12). JNK has been linked to
apoptosis (13-15). Specifically, two serine residues
(Ser63 and Ser73) in the amino-terminal
transactivation domain of c-Jun are substrates for JNK (13, 14), and
previous studies have shown that stress stimuli (e.g.
irradiation, tumor necrosis factor, sphingomyelinase, and UV light)
activate JNK (13-15). In the present study, we show that 2ME2-induced
apoptosis in MM cells is, at least in part, mediated by JNK activation,
and JNK-dependent release of Smac from mitochondria to
cytosol. Our findings provide the first evidence for the requirement of
JNK in triggering Smac-mediated apoptosis.
Cell Culture and Reagents--
Human MM.1S MM cells (11) were
grown in RPMI 1640 medium supplemented with 10%
heat-inactivated fetal bovine serum, 100 units/ml penicillin, 100 µg/ml streptomycin, and 2 mM L-glutamine. Mononuclear cells were isolated from a patient with MM (PCL
cells) by Ficoll-Hypaque density gradient centrifugation and incubated with HB-7 (anti-CD38) MoAb-biotin-streptavidin and 2H4 (anti-CD45RA) MoAb-fluorescein isothiocyanate on ice. Tumor cells (96 + 2% CD38 + 45RA-) were isolated using an Epics C cell sorter (Coulter Electronics, Hialeah, FL), washed, and resuspended in regular growth medium. Cells were treated with 3 µM of 2ME2, or 10 nM proteasome inhibitor PS-341, as described previously
(11, 16). Cells were also treated with 3 µM 2ME2 in the
presence or absence of JNK-specific inhibitor SP600125 (17).
Apoptotic Assays--
Dual fluorescence staining
with DNA-binding fluorochrome Hoechst 33342 and propidium iodide was
used to quantitate the percentage of apoptotic (propidium
iodide-Hoechst 33342+) cells by flow cytometry (The Vantage, BD
Biosciences), as described previously (11).
In Vitro Immune Complex Kinase Assays--
In
vitro immune complex c-Jun or ATF2 kinase assays were performed as
described previously (18).
Preparation of Cytosolic and Mitochondrial Extracts from MM.1S
and MM Patient Cells--
MM.1S or patient MM cells were washed twice
with phosphate-buffered saline, and the pellet was suspended in
3 volumes of ice-cold buffer A (20 mM HEPES, pH 7.5, 1.5 mM MgCl2, 10 mM KCl, 1 mM EDTA, 1 mM EGTA, 1 mM
dithiothreitol, 0.1 mM phenylmethylsulfonyl
fluoride, and 10 µg/ml leupeptin, aprotinin, and pepstatin A)
containing 250 nM sucrose. The cells were homogenized using
a Dounce homogenizer, and cytosolic or mitochondrial extracts were
isolated as described previously (19).
Western Blot Analysis--
Proteins were separated from cell
lysates by SDS-PAGE, transferred to nitrocellulose, and probed with
anti-Smac (kindly provided by Dr. Xiaodong Wang, University of Texas
Southwestern Medical Center, Dallas), anti-cyto-c
(Sigma), anti-Hsp60 (Stressgen), anti-phospho-specific JNK (New
England Biolabs), as well as anti-PARP (Pharmingen), or anti-JNK and
anti-SHP2 (Santa Cruz Biotechnology, Santa Cruz, CA) Abs. The blots
were developed by enhanced chemiluminescence (ECL), using the
manufacturer's protocol (Amersham Biosciences).
Transient Transfections--
MM.1S cells were transiently
transfected using "cell line NucleofectoTM kit V,"
according to manufacturer's instructions (Amaxa Biosystems), with vector alone or DN-JNK and cotransfected with vector containing green fluorescence protein (GFP) alone. Following transfections, GFP-positive cells were selected by flow cytometry, treated with 2ME2
(3 µM) and analyzed for cell viability as described
above. Additionally, cytosolic extracts from these cells were also
analyzed for the accumulation of Smac by Western blotting as described previously.
MTT (3-(4,5-Dimethylthiozol-2-yl)-2,5-diphenyltetrazolium
Bromide) Assays--
Cell viability was assessed by MTT (Chemicon
International Inc., Temecula, CA) assay (Roche Molecular Biochemicals),
and trypan blue exclusion, as described previously (11).
Analysis of Mitochondrial Membrane Potential
( To examine whether 2ME2 induces apoptosis in the MM.1S MM cells,
we performed flow cytometric analysis using propidium iodide and
Hoechst staining. Treatment of cells with 3 µM 2ME2 for
24 h significantly increased the percentage of apoptotic cells
(51% ± 3.6%, p < 0.005, n = 3), as
in our prior studies (11). Previous studies have shown that activation
of JNK plays an important role in apoptosis (14, 15). To examine
whether 2ME2 induces activation of JNK, MM.1S MM cells were exposed to
2ME2 for various time intervals, and JNK activity was analyzed by
in vitro immune complex kinase assays using GST-Jun as a
substrate. Analysis of anti-JNK immunoprecipitates demonstrated
significant (8-10-fold) increase in GST-Jun phosphorylation, indicating the activation of JNK (Fig.
1A, upper left
panel). Moreover, cotreatment of MM.1S cells with SP600125, a
specific inhibitor of JNK (17), blocks 2ME2-induced JNK activity (Fig. 1A, upper left panel). This activation of JNK in
response to 2ME2 does not alter JNK protein levels (Fig. 1A,
lower left panel). Increase in JNK activity was
detectable as early as 1h after 2ME2 treatment and peaked at 12 h/24 h
(Fig. 1A, upper right panel). Our findings are in
concert with those of Verheij et al. (15), which demonstrate
a role of JNK in ceramide- and tumor necrosis factor-
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES
(2), and
other substrates, ultimately leading to cell death.
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES
m) Dissipation--
MM.1S cells were treated with
2ME2 in the presence or absence of JNK inhibitor (SP600125) for 12 h, harvested, and analyzed for mitochondrial membrane potential
(
m). 2ME2 or dexamethasone-treated MM cells were
stained with lipophilic cationic dye CMXRos (Mitotracker Red)
(Molecular Probes, Eugene, OR) in phosphate-buffered saline for 20 min
at 37 °C and analyzed by flow cytometry to assay for alterations in
m.
RESULTS AND DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES
-induced
apoptosis. Moreover, coordinate regulation of JNKs, p38, and
extracellular signal-regulated kinase (ERK) kinases facilitates
apoptosis induced by withdrawal of growth factor, suggesting that
activation of JNK may be essential for apoptosis (20).
View larger version (22K):
[in a new window]
Fig. 1.
A, 2ME2 triggers JNK activation. MM.1S
cells were treated with 2ME2 (3 µM) in the presence or
absence of JNK inhibitor SP600125 (SP) (10 µM)
for the indicated time period. Lysates were immunoprecipitated with
anti-JNK Ab. Immune complex kinase assays were performed by addition of
5 µg of GST-Jun, [ -32P]ATP, and incubation
for 15 min at 30 °C. The phosphorylated proteins were resolved by
10% SDS-PAGE and analyzed by autoradiography (upper panel).
Anti-JNK immunoprecipitates were also immunoblotted with anti-JNK Ab
(lower panel). Blots are representative of three independent
experiments with similar results. MM.1S cells were also treated with
2ME2 (3 µM) for various time periods and analyzed for JNK
activity, as above (right panel). The -fold activation in
JNK activity is expressed as the mean ± S.D. of three independent
experiments. B, translocation of JNK to mitochondria in
response to 2ME2. MM.1S cells were treated with 2ME2 (3 µM) and harvested at 24 h. Cytosolic
(cyto) and mitochondrial (Mito) fractions were
isolated and subjected to immunoblotting with ant-JNK (upper
panel) or anti-Hsp60 (lower panel) Abs. Blots are
representative of two independent experiments with similar results.
C and D, SP600125 (SP), inhibitor of
JNK abrogates 2ME2-induced release of Smac or cyto-c. MM.1S
cells were treated with 2ME2 (3 µM) in the presence or
absence of SP600125 and harvested at 24 h. Cytosolic proteins were
separated by 12.5% SDS-PAGE and analyzed by immunoblotting with
anti-Smac or anti-cyto-c (C and D,
upper panels) Abs. As a control for equal loading of
proteins, filters were also reprobed with anti-SHP2 Ab (C
and D, lower panels). Blots are representative of
three independent experiments with similar results. E,
overexpression of DN-JNK block 2ME2-induced Smac release. MM.1S cells
were transiently transfected with vector alone or DN-JNK and
cotransfected with GFP. GFP-positive cells were isolated and treated
with 2ME2 (3 µM). Cytosolic extracts from these cells
were separated by SDS-PAGE and analyzed by immunoblotting with
anti-Smac (first panel). Expression of DN-SAPK
(pEBG-DN-SAPK) and endogenous JNK was detected by immunoblotting with
anti-JNK Abs (second panel). JNK activation was measured by
immunoblotting with anti-phospho-specific JNK Abs (third
panel). As a control for equal transfections, filters were
reprobed with anti-GFP Abs (fourth panel). Additional
reprobing of filters with anti-SHP2 Ab shows equal protein loading in
each lane (fifth panel). Blots are representative of four
independent experiments with similar results.
We next examined the mechanism whereby JNK mediates its apoptotic effects during 2ME2-induced apoptosis. Translocation of JNK from cytosol to the nucleus has been shown in response to osmotic stress (21). Other studies showed that JNK translocates to mitochondria after genotoxic stress and inhibits the anti-apoptotic function of proteins belonging to Bcl2 family members (22, 23), thereby allowing the release of mitochondrial apoptogenic proteins to cytosol and subsequent activation of caspase cascades. We next therefore determined whether 2ME2 induces translocation of JNK to mitochondria or nucleus in MM cells. Cytosolic, mitochondrial, and nuclear extracts from untreated and 2ME2-treated MM.1S cells were assayed for the JNK protein levels. As seen in Fig. 1B (upper panel), 2ME2 significantly increases JNK protein level in mitochondrial fraction (4-5-fold, as assessed by densitometry). Purity of mitochondria was confirmed by reprobing the blots with an antibody against mitochondrial-specific Hsp60 protein (Fig. 1B, lower panel). No increases in JNK protein levels in the nuclear fractions were detected in 2ME2-treated cells (data not shown). Together, these findings demonstrate that 2ME2-induced apoptosis is associated with both activation of JNK and its translocation to mitochondria. These results suggest a potential involvement of mitochondria during 2ME2-induced apoptosis in MM cells.
Mitochondria harbor two key modulators of apoptosis, cyto-c and Smac (second mitochondria-derived activator of caspase) or DIABLO, which are released from mitochondria into the cytosol during apoptosis (5, 6, 8, 9, 24). The upstream signal(s) that triggers the release of these proteins from mitochondria to cytosol is unclear. A recent study showed that activated JNK is required for the cyto-c release and associated apoptosis (12); however, the influence of JNK signaling on the release of Smac is presently undefined. Given that 2ME2 activates JNK in MM cells and JNK translocates to mitochondria, we next assessed whether 2ME2-induces the release of Smac and whether 2ME2-activated JNK mediates the release of Smac. MM.1S cells were treated with 2ME2, in the presence or absence of JNK inhibitor SP600125; cytosolic extracts were prepared and subjected to immunoblot analyses with anti-Smac Ab. As seen in Fig. 1C (upper panel), 2ME2 induces the release of Smac, as in our previous study (11). Importantly, cotreatment with SP600125 significantly inhibits the release of Smac (Fig. 1C, upper panel). Reprobing the immunoblots with anti-SHP2 (as control) confirms equal protein loading (Fig. 1C, lower panel). These findings demonstrate that 2ME2-induced JNK activation is required for the mitochondrial release of Smac. Examination of the effects of 2ME2 on the release of cyto-c, as well as requirement of JNK for the release of cyto-c, demonstrated similar results (Fig. 1D). To further address this issue, we transiently transfected MM.1S cells with either dominant-negative mutant of JNK (pEBG-DN-JNK) or control vector; following treatment with 2ME2, cytosolic extracts were analyzed for accumulation of Smac in the cytosol. As seen in Fig. 1E (first panel), overexpression of DN-JNK abrogates the 2ME2-induced release of Smac from mitochondria to cytosol. To confirm the expression of endogenous JNK and exogenous DN-JNK (GST-DN-JNK), filters were reprobed with anti-JNK antibody (Fig. 1E, second panel). Immunoblotting with phospho-specific JNK antibody showed a marked decrease in 2ME2-induced JNK activity in cells transfected with DN-JNK compared with empty vector (Fig. 1E, third panel), which confirmed the function of DN-JNK. Immunoblotting with anti-GFP and anti-SHP2 Abs demonstrated equal transfection efficiency and protein loading, respectively (Fig. 1E, fourth and fifth panels). To further confirm the specificity of DN-JNK, we examined lysates from DN-JNK transfected cells for both p38 MAPK and JNK activity using GST-ATF2 and GST-Jun as substrates, in an in vitro immune complex kinase assays. DN-JNK blocked 2ME2-induced JNK, but not p38MAPK activity (data not shown). Taken together, these results demonstrate that JNK is required for the release of Smac during 2ME2-induced apoptosis in MM cells.
We next determined the functional significance of 2ME2-induced JNK
activation. MM.1S cells were transiently transfected with either DN-JNK
or empty vector and treated with 2ME2. As seen in Fig.
2A, after treatment with 2ME2, MM.1S
DN-JNK transfectants survived significantly longer than cells
transfected with vector alone: median viability was 48% (24 h) and
24% (48 h) after 2ME2 treatment of empty vector transfected cells
versus 73% (24 h) and 45% (48 h) after 2ME2 treatment of
DN-JNK transfected MM.1S cells (p = 0.05, as determined
by one-sided Wilcoxon rank-sum test). Similar results were obtained in
MM.1S cells treated with 2ME2 in the presence or absence of JNK
inhibitor (Fig. 2B). As a control for specificity of a JNK
inhibitor SP600125, we also treated cells with 2ME2 in the presence or
absence of p38MAPK inhibitor. As seen in Fig. 2B, in
contrast to SP600125, p38MAPK inhibitor does not attenuates
2ME2-induced cytotoxicity. Moreover, blockade of JNK also inhibits
2ME2-induced PARP cleavage, a signature event during apoptosis (Fig.
2C). Other studies have reported that a decrease in
mitochondrial membrane potential (m) causes release of
Smac and cyto-c (5, 9), and we therefore asked whether
2ME2-induced apoptosis correlates with changes in
m, and
whether inhibition of JNK affects the
m. As seen in Fig.
2D, 2ME2 triggers a significant decrease in
m, and conversely, cotreatment with JNK inhibitor SP600125 prevents 2ME2-induced reduction in
m. Together, these data
suggest that blockade of JNK decreased 2ME2-induced apoptosis. Our
prior study demonstrated that 2ME2-induced apoptosis is associated with activation of caspase-8 and -9 (11), and both are known to activate downstream caspase-3 and PARP cleavage. In contrast to caspase-9, caspase-8-mediated apoptotic signaling may proceed independent of
cyto-c or Smac release. It is likely, therefore, that the
caspase-8 pathway may still be operative in response to 2ME2 despite
the expression of DN-JNK, which may explain for the lack of complete protection provided by DN-JNK against 2ME2-induced apoptosis. Moreover,
other upstream molecules besides JNK may modulate 2ME2-triggered Smac
release, and further studies are required to understand these mechanisms. Nevertheless our present findings demonstrate that JNK, at
least in part, mediates 2ME2-induced apoptosis in MM cells.
|
To determine whether other apoptotic inducers in MM cells similarly
affect the JNK-Smac signaling pathways, we treated MM.1S cells with a
proteasome inhibitor PS-341 (10 nM) in the presence or
absence of SP600125, and cell extracts were analyzed for both JNK
activity and accumulation of Smac in the cytosol. PS-341
treatment of MM.1S cells triggers significant JNK activity, as well as
release of Smac (Fig. 3, A and
B, upper panels). Cotreatment with JNK inhibitor
significantly blocks the PS-341-triggered release of Smac (Fig. 3,
A and B, upper panels), further
confirming the requirement of JNK for release of Smac. Furthermore,
similar results were obtained when patient MM (PCL) cells were exposed
to 2ME2 (Fig. 3C).
|
Exogenous JNK has been shown to phosphorylate many mitochondrial proteins during apoptosis (23); however, not all apoptotic agents trigger a sequential activation of JNK and mitochondrial pathways (25, 26). Our prior studies showed that dexamethasone-induced apoptosis in MM.1S occurs independent of JNK activation, but is associated with Smac release (18). The observation that 2ME2 induces JNK activation in MM.1S cells suggest that JNK signaling is not defective in these cells. This is in concert with other studies demonstrating that anti-Fas-induced apoptosis is associated with the release of cyto-c in JNK-deficient mouse embryonic fibroblast cells, whereas UV-induced apoptosis in these same cells requires JNK activation for release of cyto-c (12). These findings indicate that both activation of JNK and its requirement for the release of mitochondrial proteins are stimuli-specific.
Collectively, our present study shows that two distinct apoptotic
agents in MM cells induce JNK, which upon activation translocates to
mitochondria and triggers the release of Smac. Inhibition of JNK
activation by either DN-JNK or a specific inhibitor of JNK disables JNK-mediated Smac release and associated apoptosis. Finally, our findings have important biologic and therapeutic implications. Given that synthetic Smac peptides enhance the apoptotic activity of
chemotherapeutic agents (27), coupled with our present results showing
that anti-MM drugs induce apoptosis via release of mitochondrial Smac,
suggest that Smac agonists or active Smac peptides may sensitize MM
cells to 2ME2 or PS-341-induced cell death.
![]() |
ACKNOWLEDGEMENTS |
---|
We thank Dr. Xiaodong Wang for providing Smac-related reagents and helpful suggestions, as well as J. Kyriakis and L. Zon for SAPK cDNA constructs.
![]() |
FOOTNOTES |
---|
* This work was supported by National Institutes of Health Grants 50947 and CA 78373, a Doris Duke Distinguished Clinical Research Scientist Award (to K. C. A.), The Myeloma Research Fund, and The Cure Myeloma Fund.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Present address: ILEX Oncology Inc., Boston, MA 02215.
§ To whom correspondence and reprint requests should be addressed: Dana-Farber Cancer Inst., 44 Binney St., Boston, MA 02215. Tel.: 617-632-2144; Fax: 617-632-2140; E-mail: kenneth_anderson@dfci.harvard.edu.
Published, JBC Papers in Press, March 28, 2003, DOI 10.1074/jbc.C300076200
![]() |
ABBREVIATIONS |
---|
The abbreviations used are: PARP, poly(ADP-ribose) polymerase; Smac, second mitochondria-derived activator of caspases; cyto-c, cytochrome c; MM, multiple myeloma; 2ME2, 2-methoxyestradiol; PS-341, proteasome inhibitor-341; SAPK, stress-activated protein kinase; JNK, c-Jun NH2-terminal kinase; Ab, antibody; MoAb, monoclonal Ab; DN, dominant-negative; GFP, green fluorescence protein; MTT, 3-(4,5-dimethylthiozol-2-yl)-2,5-diphenyltetrazolium bromide; GST, glutathione S-transferase.
![]() |
REFERENCES |
---|
![]() ![]() ![]() ![]() ![]() ![]() |
---|
1. | Willie, A. H., Kerr, J. F., and Currie, A. R. (1980) Int. Rev. Cytol. 68, 251-306[Medline] [Order article via Infotrieve] |
2. |
Thornberry, N. A.,
and Lazebnik, Y.
(1998)
Science
281,
1312-1316 |
3. | Chinnaiyan, A. M., and Dixit, V. M. (1996) Curr. Biol. 6, 555-562[Medline] [Order article via Infotrieve] |
4. | Oberhammer, F. A., Hochegger, K., Froschl, G., Tiefenbacher, R., and Pavelka, M. (1994) J. Cell Biol. 126, 827-837[Abstract] |
5. | Liu, X., Naekyung Kim, C., Yang, J., Jemmerson, R., and Wang, X. (1996) Cell 86, 147-157[Medline] [Order article via Infotrieve] |
6. |
Yang, J.,
Liu, X.,
Balla, K.,
Kim, C. N.,
Ibardo, N. M.,
Cai, J.,
Peng, T. i.,
Jones, D. P.,
and Wang, X.
(1997)
Science
275,
1129-1136 |
7. |
Hu, Y.,
Wu, D.,
Inohara, N.,
and Nunez, G.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
4386-4391 |
8. |
Srinivasula, S. M.,
Datta, P.,
Fan, X. J.,
Fernandes-Alnemri, T.,
Huang, Z.,
and Alnemri, E. S.
(2000)
J. Biol. Chem.
275,
36152-36157 |
9. | Du, C., Fang, M., Li, Y., Li, L., and Wang, X. (2000) Cell 102, 33-42[Medline] [Order article via Infotrieve] |
10. | Verhagen, A. M., Ekert, P. G., Pakusch, M., Silke, J., Connolly, L. M., Reid, G. E., Moritz, R. L., Simpson, R. J., and Vaux, D. L. (2000) Cell 102, 43-53[Medline] [Order article via Infotrieve] |
11. |
Chauhan, D.,
Catley, L.,
Hideshima, T.,
Li, G.,
Leblanc, R.,
Gupta, D.,
Sattler, M.,
Richardson, P.,
Schlossman, R. L.,
Podar, K.,
Weller, E.,
Munshi, N.,
and Anderson, K. C.
(2002)
Blood
100,
2187-2194 |
12. |
Tournier, C.,
Hess, P.,
Yang, D. D.,
Xu, J.,
Turner, T. K.,
Nimnual, A.,
Bar-Sagi, D.,
Jones, S. N.,
Flavell, R. A.,
and Davis, R. J.
(2000)
Science
288,
870-874 |
13. |
Kyriakis, J. M.,
and Avruch, J.
(1996)
J. Biol. Chem.
271,
24313-24316 |
14. | Derijard, B., Hibi, M., Wu, I. H., Barrett, T., Su, B., Deng, T., Karin, M., and Davis, R. J. (1994) Cell 76, 1025-1037[Medline] [Order article via Infotrieve] |
15. | Verheij, M., Bose, R., Lin, X. H., Yhao, B., Jarvis, W. D., Grant, S., Birrer, M. J., Szabo, E., Zon, L. I., Kyriakis, J. M., Haimovitz-Friedman, A., Fuks, Z., and Kolesnick, R. N. (1996) Nature 380, 75-79[CrossRef][Medline] [Order article via Infotrieve] |
16. |
Hideshima, T.,
Richardson, P.,
Chauhan, D.,
Palombella, V. J.,
Elliott, P. J.,
Adams, J.,
and Anderson, K. C.
(2001)
Cancer Res.
61,
3071-3076 |
17. |
Bennett, B. L.,
Sasaki, D. T.,
Murray, B. W.,
O'Leary, E. C.,
Sakata, S. T.,
Xu, W.,
Leisten, J. C.,
Motiwala, A.,
Pierce, S.,
Satoh, Y.,
Bhagwat, S. S.,
Manning, A. M.,
and Anderson, D. W.
(2001)
Proc. Natl. Acad. Sci. U. S. A.
98,
13681-13686 |
18. | Chauhan, D., Pandey, P., Ogata, A., Teoh, G., Treon, S., Urashima, M., Kharbanda, S., and Anderson, K. C. (1997) Oncogene 15, 837-843[CrossRef][Medline] [Order article via Infotrieve] |
19. |
Chauhan, D.,
Hideshima, T.,
Rosen, S.,
Reed, J. C.,
Kharbanda, S.,
and Anderson, K. C.
(2001)
J. Biol. Chem.
276,
24453-24456 |
20. | Xia, Z., Dickens, M., Raingeaud, J., Davis, R. J., and Greenberg, M. E. (1995) Science 270, 1326-1331[Abstract] |
21. | Kawasaki, H., Moriguchi, T., Matsuda, S., Li, H. Z., Nakamura, S., Shimohama, S., Kimura, J., Gotoh, Y., and Nishida, E. (1996) Eur. J. Biochem. 241, 315-321[Abstract] |
22. |
Kharbanda, S.,
Saxena, S.,
Yoshida, K.,
Pandey, P.,
Kaneki, M.,
Wang, Q.,
Cheng, K.,
Chen, Y. N.,
Campbell, A.,
Sudha, T.,
Yuan, Z. M.,
Narula, J.,
Weichselbaum, R.,
Nalin, C.,
and Kufe, D.
(2000)
J. Biol. Chem.
275,
322-327 |
23. | Kroemer, G., and Reed, J. C. (2000) Nat. Med. 6, 513-519[CrossRef][Medline] [Order article via Infotrieve] |
24. | Chai, J., Du, C., Wu, J. W., Kyin, S., Wang, X., and Shi, Y. (2000) Nature 406, 855-862[CrossRef][Medline] [Order article via Infotrieve] |
25. |
Gibson, E. M.,
Henson, E. S.,
Villanueva, J.,
and Gibson, S. B.
(2002)
J. Biol. Chem.
277,
10573-10580 |
26. |
Morishima, N.,
Nakanishi, K.,
Takenouchi, H.,
Shibata, T.,
and Yasuhiko, Y.
(2002)
J. Biol. Chem.
277,
34287-34294 |
27. |
Arnt, C. R.,
Chiorean, M. V.,
Heldebrant, M. P.,
Gores, G. J.,
and Kaufmann, S. H.
(2002)
J. Biol. Chem.
277,
44236-44243 |